Kenvue Inc. Common Stock vs Lionsgate Studios Corp Common Shares — how do they compare? Kenvue Inc. Common Stock trades at $18.15 (market cap $34.11B), while Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B). The key difference: Kenvue Inc. Common Stock is far larger — about 10.3× Lionsgate Studios Corp Common Shares's market cap, and Kenvue Inc. Common Stock pays a 4.73% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kenvue Inc. Common Stock for 1 Days and Lionsgate Studios Corp Common Shares for 0 Days on average.
| KVUE | LION | |
|---|---|---|
Market Cap | $34.11B | $3.31B |
Volume | 27,388,811 | 2,146,134 |
Sector | Consumer Staples | Technology |
52-Week High | $19.83 | $16.40 |
52-Week Low | $14.11 | $5.91 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $41.62B | $6.82B |
Dividend Yield | 4.73% | — |
Signals from Pluang's Aura AI — not financial advice
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →